Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Thyroid Cancer
Treatment for Advanced Thyroid Cancer
Read More
Ovarian Cancer
Telehealth Coverage Expanded During the COVID-19 Pandemic
Read More
Ovarian Cancer
Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care
Read More
Ovarian Cancer
NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months
Read More
Practical Issues in Pharmacy Management
Exploring the Occupational Hazards Associated with Antineoplastic Agents
Jeff Lombardo, PharmD, BCOP
Read More
FDA Updates
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
Meeting Highlights
ESMO Highlights
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Read More
Original Research
,
Transplant
,
Adverse Events
Horsies and Bunnies: Comparing Antithymocyte Globulin Drugs in Patients Undergoing Allogeneic Stem-Cell Transplant
Crystal Lu, PharmD, BCOP
,
Nancy Mikulandric, PharmD, BCOP
,
Meredith Grycki, PharmD, BCOP, BCPS
,
Vishnuprabha Vogel, PharmD, BCOP, BCPS
,
Shatha Farhan, MD
,
Edward Peres, MD
,
Nalini Janakiraman, MD
,
Klodiana Neme, PharmD, BCOP
Crystal Lu, PharmD, BCOP; Nancy Mikulandric, PharmD, BCOP; Meredith Grycki, PharmD, BCOP, BCPS; Vishnuprabha Vogel, PharmD, BCOP, BCPS; Shatha Farhan, MD; Edward Peres, MD; Nalini Janakiraman, MD; Klodiana Neme, PharmD, BCOP
Read More
126
127
128
129
130
131
132
Page 129 of 199
Results 1281 - 1290 of 1986
